(Recombinant interferon beta), identical to the native molecule and registered for the treatment of multiple sclerosis and several viral diseases, licensed to Inter-Lab Ltd., a Serono company.
- Indicated for Multiple Sclerosis Rebif is a recombinant interferon beta 1a.
- Rebif is marketed worldwide by Merck Serono.
- 1982: Licensed to Interpharm.
- 2007 Sales: Euro 1.2 Billion
- 2007 Market share: 32%